BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 9, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2023

View Archived Issues
Illustration of Alzheimer’s in the brain.

Study identifies cause of death for Alzheimer’s neurons

By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new insights into how amyloid plaques, tau tangles and neuronal death are related at the molecular level. Read More

IRX-4647 promotes anticancer immune response in combination treatments

Retinoic acid (RA) is fundamental to maintain immune homeostasis. In this process, RA induces regulatory T cells and promotes tolerance, but depending on the conditions, RA may also promote inflammation and tissue damage. Read More
RNA strand

Biontech and CEPI partner to develop mRNA mpox vaccine candidates

Biontech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) have established a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT-166 for the prevention of mpox (formerly monkeypox). Read More
Cancer cells being destroyed by immunotherapy

Medigene selects lead candidate for TCR-T therapy program MDG-2011

Medigene AG has selected its lead candidate for MDG-2011, a T-cell receptor engineered T-cell (TCR-T) therapy targeting KRAS G12V with HLA-A*11 and being developed in combination with the company’s PD1-41BB costimulatory switch protein (CSP) technology. Read More

Cancer Research Technology patents new PROTACs targeting ERK5 for cancer

Cancer Research Technology Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently bonded to a mitogen-activated protein kinase 7 (MAPK7; ERK5)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer. Read More
cancer-cell-light.png

[177Lu]NGR-RGD-AB, a novel albumin binder radiolabeled heterodimer for theranostic use

Integrin alphavbeta3 and aminopeptidase N (CD13) are important biomarkers involved in tumor angiogenesis, tumor growth and metastasis. Peptides RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) are the most studied peptides for targeting integrin alphavbeta3 and CD13, respectively. Read More
Antibiotic resistant bacteria inside a biofilm

Contrafect files IND for CF-370 for hospital-acquired and ventilator-associated bacterial pneumonias

Contrafect Corp. has submitted an IND application to the FDA for its intravenous antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Read More

Inversago Pharma divulges new cannabinoid CB1 receptor antagonists

Inversago Pharma Inc. has synthesized cannabinoid CB1 receptor antagonists reported to be useful for the treatment of cancer, diabetes, fibrosis, hypertension, irritable bowel syndrome, metabolic syndrome, alopecia and Prader-Willi syndrome. Read More

Insusense describes new sortilin antagonists

Insusense ApS has identified sortilin (NT3; Gp95) antagonists reported to be useful for the treatment of neurodegeneration, cancer, pain, diabetes, diabetic retinopathy, glaucoma, hearing loss and cardiovascular disorders, among others. Read More
Pancreas

Researchers present [124I]IMMU-132, a Trop2-targeting PET probe

Researchers from Peking University Cancer Hospital presented the discovery and preclinical evaluation of [124I]IMMU-132, a trophoblast cell surface antigen 2 (Trop2)-targeting molecular probe for micro-PET imaging. Read More

Sichuan University presents new metallo-β-lactamase inhibitors

Sichuan University has divulged metallo-β-lactamase (MBL; bacterial) inhibitors reported to be useful for the treatment of bacterial infections. Read More

Canadian researchers discover new BAX and/or BAK inhibitors for neurodegenerative disorders

Researchers at Ontario Institute for Cancer Research and Sunnybrook Research Institute have described isoquinoline derivatives acting as apoptosis regulator BAX and/or BAK inhibitors reported to be useful for the treatment of neurodegenerative disorders. Read More
Photomicrograph of hepatocellular carcinoma

TMHA-37, a potent Nur77 modulator with cytotoxicity against HCC cell lines

Researchers from Xiamen University and affiliated organizations have reported the discovery of nuclear hormone receptor NUR/77 (Nur77) modulators as potential candidates for the treatment of hepatocellular carcinoma (HCC). Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 8, 2025.
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • IV drips

    ASH 2025: New blood cancer therapies trump chemo, older drugs

    BioWorld
    Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing